RAMM Pharma

RAMM Pharma Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of RAMM Pharma (RAMM.CN) as of Oct 24, 2026 is 11.90 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 24.23 % — a change of -50.90% (lower).

Cash Conversion

11.90 %

YoY

-50.90%

Last updated:

Cash Conversion Rate (OCF/Net Income) of RAMM Pharma is 2025 11.90 % . Cash Conversion Rate (OCF/Net Income) of RAMM Pharma was 2024 24.23 % . It decreases by -50.90% lower compared to the previous year.

The RAMM Pharma Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
-247.27 CAD
Jan 1, 2019
26.52 CAD
Jan 1, 2020
39.22 CAD
Jan 1, 2021
53.90 CAD
Jan 1, 2022
28.21 CAD
Jan 1, 2023
56.19 CAD
Jan 1, 2024
24.23 CAD
Jan 1, 2025
11.90 CAD
The RAMM Pharma Cash Conversion history
YEARCash ConversionYoY
11.90 %-50.90%
24.23 %-56.88%
56.19 %+99.17%
28.21 %-47.66%
53.90 %+37.42%
39.22 %+47.92%
26.52 %-110.72%
-247.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RAMM Pharma Stock analysis

What does RAMM Pharma do? RAMM Pharma Corp generates revenue through cannabinoid pharmaceuticals and cannabis-based products, with brands like NettaLife, NettaPet, NettaPet Senior, NettaPet Puppies, and NettaVet targeting pet owners and veterinary markets. The company also sells cosmetics under the Cannabipiel line, including Cannabipiel Nite, Cannabipiel Body Lotion, and Cannabipiel Shampoo, catering to consumers seeking cannabinoid-infused skincare and personal care solutions. Subsidiaries such as Canapar Corp. and Medic Plast SA support production and commercialization across pharmaceutical specialties, household products, and food sectors. The firm’s product portfolio spans pharmaceuticals, pet care, cosmetics, and household items, with NettaPet and NettaVet focusing on animal health and Cannabipiel products targeting human skincare. Revenue streams include direct sales of branded items like Cannabipiel Tite and Cannabipiel Cleaning Emulsion to retail and specialty markets, while subsidiaries handle manufacturing and export operations for global distribution. Brands like Glediser SA and Yurelan SA contribute to the commercialization of diverse product categories under the company’s umbrella. RAMM Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RAMM Pharma stock

Cash Conversion Rate (OCF/Net Income) of RAMM Pharma is 11.90 % in 2025.

Cash Conversion Rate (OCF/Net Income) of RAMM Pharma changed from 24.23 % to 11.90 %, representing a -50.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) RAMM Pharma since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s RAMM Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — RAMM Pharma

All Key Metrics — RAMM Pharma